ENGN · enGene Therapeutics Inc.
enGene Therapeutics Inc (ENGN)
What's happening
- ENGN is down 1.84% today, trading at $1.86. — Live quote
- Volume today (3,851) is well below its 3-month average of 1,543,490. (Finnhub fundamentals)
- Reports earnings on 2026-09-09, 6 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.43 actual vs. $-0.48 estimated (+10.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-09-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Apr '26 | Jan '26 | Jul '25 | Apr '25 | Jan '25 |
|---|---|---|---|---|---|
| Market cap | $513.2M | — | — | $202.0M | — |
| P/E | -4.47 | — | — | -2.54 | — |
| Price/Book | 2.01 | — | — | 0.89 | — |
| EV/EBITDA | -4.04 | — | — | — | — |
| ROE | -44.98% | — | — | -35.00% | — |
| ROA | -37.33% | — | — | -29.84% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-08-11; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -61.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ENGN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Apr '26 | Jan '26 | Jul '25 | Apr '25 | Jan '25 | Jul '24 | Apr '24 | Jan '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$32.0M | -$31.2M | -$29.9M | -$27.1M | -$26.6M | -$16.8M | -$17.3M | -$10.8M |
| Net income | -$30.2M | -$29.8M | -$29.0M | -$25.8M | -$24.6M | -$14.1M | -$15.0M | -$10.7M |
| EPS (diluted) | $-0.43 | $0.44 | $0.57 | $-0.51 | $0.48 | $0.32 | $0.38 | $0.46 |
| EPS (basic) | $-0.43 | $0.44 | $0.57 | $-0.51 | $0.48 | $0.32 | $0.38 | $0.46 |
Balance sheet
| Line item | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $307.5M | $337.1M | $221.5M | $245.6M | $266.7M | $285.9M | $311.2M | $266.9M |
| Total liabilities | $52.4M | $55.6M | $53.8M | $44.9M | $39.4M | $36.0M | $38.6M | $36.5M |
| Stockholders' equity | $255.2M | $281.5M | $167.7M | $200.7M | $227.3M | $249.9M | $272.6M | $230.3M |
| Total current assets | $270.0M | $289.2M | $201.4M | $211.3M | $228.0M | $222.3M | $247.4M | $262.7M |
| Total current liabilities | $21.5M | $24.6M | $32.0M | $20.4M | $18.0M | $13.0M | $14.7M | $13.5M |
| Cash & equivalents | $29.8M | $36.6M | $50.2M | $32.6M | $57.5M | $62.3M | $173.0M | $257.7M |
| Marketable securities (current) | $228.6M | $239.3M | $143.6M | $169.3M | $159.8M | $151.5M | $65.3M | — |
| Marketable securities (non-current) | $26.7M | $36.6M | $8.5M | $23.0M | $34.1M | $59.0M | $59.5M | — |
| Property, plant & equipment | $2.3M | $2.4M | $2.5M | $1.9M | $1.6M | $1.4M | $1.2M | $1.0M |
| Other non-current assets | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.6M | $1.4M | $1.4M |
| Accounts payable | $1.8M | $2.4M | $6.7M | $2.4M | $1.6M | $2.6M | $1.4M | $2.9M |
| Common stock & paid-in capital | $632.0M | $632.0M | $513.3M | $510.2M | $510.1M | $509.8M | $509.8M | $453.5M |
| Retained earnings | -$432.0M | -$401.8M | -$372.0M | -$334.2M | -$305.2M | -$279.3M | -$254.7M | -$239.4M |
| Accumulated other comprehensive income (loss) | -$1.1M | -$842.0K | -$888.0K | -$1.2M | -$969.0K | -$1.3M | -$1.4M | -$1.0M |
Cash flow
| Line item | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$30.5M | -$28.9M | -$25.0M | -$25.6M | -$22.9M | -$25.7M | -$19.6M | -$7.2M |
| Investing cash flow | $23.6M | -$126.3M | $40.5M | $1.4M | $17.9M | -$85.0M | -$125.3M | -$2.0K |
| Financing cash flow | $74.0K | $141.7M | $2.0M | -$667.0K | $199.0K | $1.0K | $60.2M | $51.0K |
| Free cash flow | -$30.6M | -$29.1M | -$25.4M | -$26.3M | -$23.0M | -$26.0M | -$19.8M | -$7.2M |
| Capital expenditures | $98.0K | $153.0K | $437.0K | $704.0K | $45.0K | $299.0K | $238.0K | $2.0K |
| Depreciation & amortization | $200.0K | $189.0K | $398.0K | $100.0K | $100.0K | $102.0K | $220.0K | $100.0K |
| Share-based compensation | $4.1M | $2.8M | $2.6M | $2.6M | $2.6M | $1.8M | $1.7M | $1.5M |
| Change in accounts payable | -$625.0K | -$4.3M | $4.0M | $818.0K | -$974.0K | $1.1M | -$1.4M | $2.6M |
| Purchases of investments | $50.2M | $169.2M | $7.7M | $44.7M | $13.8M | $94.7M | $125.0M | — |
| Dividends paid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Oct '25 | Oct '24 | Oct '23 | Oct '22 |
|---|---|---|---|---|
| Operating income | -$123.2M | -$62.3M | -$26.1M | -$19.4M |
| Net income | -$117.3M | -$55.1M | -$99.9M | -$24.5M |
| EPS (diluted) | $2.29 | $1.46 | $151.22 | $44.30 |
| EPS (basic) | $2.29 | $1.46 | $151.22 | $44.30 |
Balance sheet
| Line item | Oct '25 | Oct '24 | Oct '23 | Oct '22 | Oct '21 |
|---|---|---|---|---|---|
| Total assets | $221.5M | $311.2M | $87.0M | $23.9M | — |
| Total liabilities | $53.8M | $38.6M | $14.5M | $47.4M | — |
| Stockholders' equity | $167.7M | $272.6M | $72.5M | -$76.6M | -$53.4M |
| Total current assets | $201.4M | $247.4M | $85.4M | $22.6M | — |
| Total current liabilities | $32.0M | $14.7M | $5.3M | $5.1M | — |
| Cash & equivalents | $50.2M | $173.0M | $81.5M | $20.4M | — |
| Marketable securities (current) | $143.6M | $65.3M | — | — | — |
| Marketable securities (non-current) | $8.5M | $59.5M | — | — | — |
| Property, plant & equipment | $2.5M | $1.2M | $589.0K | $387.0K | — |
| Other non-current assets | $1.4M | $1.4M | $930.0K | $939.0K | — |
| Accounts payable | $6.7M | $1.4M | $1.2M | $723.0K | — |
| Common stock & paid-in capital | $513.3M | $509.8M | $259.4M | $16.4M | — |
| Retained earnings | -$372.0M | -$254.7M | -$199.6M | -$99.7M | — |
| Accumulated other comprehensive income (loss) | -$888.0K | -$1.4M | -$1.0M | -$1.0M | — |
Cash flow
| Line item | Oct '25 | Oct '24 | Oct '23 | Oct '22 |
|---|---|---|---|---|
| Operating cash flow | -$99.2M | -$48.3M | -$24.7M | -$17.6M |
| Investing cash flow | -$25.1M | -$126.0M | -$318.0K | -$153.0K |
| Financing cash flow | $1.5M | $265.7M | $86.1M | $28.0M |
| Free cash flow | -$100.7M | -$49.2M | -$25.1M | -$17.7M |
| Capital expenditures | $1.5M | $925.0K | $318.0K | $153.0K |
| Depreciation & amortization | $500.0K | $300.0K | $200.0K | $200.0K |
| Share-based compensation | $9.6M | $5.3M | $3.5M | $116.0K |
| Change in accounts payable | $4.9M | $474.0K | $373.0K | -$197.0K |
| Purchases of investments | $160.8M | $125.0M | — | — |
| Dividends paid | — | — | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ENGN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:54 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-07-17 | 8-K | 2026-07-17 | View on SEC.gov → |
| 2026-07-16 | 8-K | 2026-07-15 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-15 | 10-Q | 2026-04-30 | View on SEC.gov → |
Recent news
Headlines about ENGN (enGene Therapeutics Inc.). Links open the publisher — we don’t host full articles.
-
enGene to Participate in Upcoming Investor Conferences
Yahoo Finance · 2026-09-01 -
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
Yahoo Finance · 2026-08-13 -
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
Seeking Alpha · 2026-08-11 -
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer - Slideshow
Seeking Alpha · 2026-08-11 -
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
Yahoo Finance · 2026-08-04 -
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Yahoo Finance · 2026-07-16 -
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
Yahoo Finance · 2026-07-15 -
Neumora depression drug fails; EnGene to cut 50% of staff
Yahoo Finance · 2026-06-16
No headlines in this category right now — try “All”.